In a preprint published at CellPress researchers found that SARS-CoV-2 virus share attach vector with the 2003 SARS-CoV, called ACE2, for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use was found to  block entry and may constitute a treatment option. The research team also found that the sera from convalescent SARS patients neutralized SARS-2-S-driven entry.

These results indicate possible antiviral intervention for COVID-19 patients.